FY results 2024

Positioned for strong growth

FY 2024 documents

Market leader in peptide API manufacturing and services

PolyPeptide is a Contract Development & Manufacturing Organization (CDMO) supporting pharmaceutical and biotech companies in the development and manufacturing of proprietary and generic active pharmaceutical ingredients (API). 

Media releases

PolyPeptide publishes invitation to the annual General Meeting 2025

18 Mar 2025 - Baar, 18 March 2025 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide-based active pharmaceutical ingredients, published today the invitation to the fourth […]

Read more
Ad hoc announcements pursuant to Art. 53 LR

PolyPeptide with substantial improvements in profitability and cash flow, positioned for strong growth

11 Mar 2025 - Baar, 11 March 2025 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced its annual results for 2024 […]

Read more

PolyPeptide video

PolyPeptide Group - Ahead on green peptide chemistry